Last Updated : August 4, 2015
Details
FilesGeneric Name:
Sacubitril/valsartan
Project Status:
Complete
Therapeutic Area:
Heart failure, NYHA class II or III
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Call for patient/clinician input open:
Brand Name:
Entresto
Project Line:
Reimbursement Review
Project Number:
SR0447-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Submission Type:
Initial
Indications:
Heart failure, NYHA class II or III
Recommendation Type:
List with clinical criteria and/or conditions
Final Recommendation:
Request for Resubmission: Eligible (Decision Date: January 6, 2020)
Files
Last Updated : August 4, 2015